By vgreene, 18 May, 2020 No Evidence of Clinical Efficacy of Hydroxychloroquine in Patients Hospitalized for COVID-19 Infection and Requiring Oxygen: Results of a Study Using Routinely Collected Data to Emulate a Target Trial; pre-print medRxiv article
By vgreene, 18 May, 2020 Association of Treatment With Hydroxychloroquine or Azithromycin With In Hospital Mortality in Patients With COVID 19 in New York State
By vgreene, 18 May, 2020 Study considerations: retrospective, random sampling; imbalanced baseline characteristics; treatment bias; varied dosing and duration; possible missed readmissions; ADRs at any time during hospital visit, potentially prior to tx
By vgreene, 18 May, 2020 Abnormal ECG more common in HCQ+AZ (27%) and HCQ (27%) vs AZ (16%) and no tx (14%), but no difference in adjusted analysis; more pts w/ cardiac arrest in HCQ+AZ (16%) and HCQ (14%) vs AZ (6%) and no tx (7%)
By vgreene, 18 May, 2020 Unadjusted analysis for in-hospital mortality (overall 20%), HCQ+AZ 26%, HCQ 20%, AZ 10%, no tx 13%; adjusted analysis for in-hospital mortality showed no differences when comparing pts w/ no tx to each drug group, and when comparing HCQ vs AZ
By vgreene, 18 May, 2020 Retrospective multicenter cohort study; 1,438 randomly selected hospitalized pts (median age 63y) in NYC metro area w/ confirmed COVID-19 treated w/ HCQ (n=271) or AZ (n=211) alone, HCQ+AZ (n=735), or no tx (n=221); significant imbalances btwn groups, inc
By vgreene, 18 May, 2020 VTE prophylaxis recommended at usual ppx dosing for all nonpregnant pts hospitalized w COVID 19 eval for thromboembolic dz if rapid deterioration or sudden perfusion loss1 2
By vgreene, 18 May, 2020 VTE prophylaxis recommended at usual ppx dosing for all nonpregnant pts hospitalized w COVID 19 eval for thromboembolic dz if rapid deterioration or sudden perfusion loss1 2
